Metformin use in chronic kidney disease: New evidence to guide dosing

QJM: An International Journal of Medicine

Volumn 106, Issue 11, 2013, Pages 1059-1061

  Herrington, W G ^a   Nye, H J ^b   Aung, T ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b ROYAL BERKSHIRE NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; METFORMIN; SULFONYLUREA DERIVATIVE; GLUCOSE BLOOD LEVEL; PHARMACOLOGICAL BIOMARKER;

ARTICLE; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DEHYDRATION; DIARRHEA; DRUG CLEARANCE; DRUG EXPOSURE; DRUG SAFETY; DYSPNEA; GENETIC VARIABILITY; HUMAN; HYPOGLYCEMIA; KIDNEY FUNCTION; LACTIC ACIDOSIS; LETHARGY; LIVER CELL; PRIORITY JOURNAL; VOMITING; CHEMICALLY INDUCED; GLUCOSE BLOOD LEVEL; METABOLISM; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR;

ACIDOSIS, LACTIC; BIOMARKERS, PHARMACOLOGICAL; BLOOD GLUCOSE; HUMANS; METFORMIN; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84886995460     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hct155     Document Type: Article

References (11)

1. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:854-65.
2. Nye HJ, Herrington WG. Metformin: the safest hypoglycaemic agent in chronic kidney disease? Nephron Clin Pract 2011; 118:c380-3.
3. Lalau JD, Race JM. Lactic acidosis in metformin therapy: searching for a link with metformin in reports of 'metformin-associated lactic acidosis'. Diabetes Obes Metab 2001; 3:195-201.
4. NICE Clinical Guideline CG87 (May 2009). Type 2 diabetes-newer agents (a partial update of CG66). www. nice.org.uk/cg87 (1 May 2013, date last accessed).
5. Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care 2011; 34:1431-7.
6. Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 2011; 50:81-98.
7. Duong JK, Kumar SS, Kirkpatrick CM, Greenup LC, Arora M, Lee TC, et al. Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: simulation of doses according to renal function. Clin Pharmacokinet 2013; 52:373-84.
8. Duong JK, Roberts DM, Furlong TJ, Kumar SS, Greenfield JR, Kirkpatrick CM, et al. Metformin therapy in patients with chronic kidney disease. Diabetes Obes Metab 2012; 14:963-5.
9. Lalau JD, Lemaire-Hurtel AS, Lacroix C. Establishment of a database of metformin plasma concentrations and erythrocyte levels in normal and emergency situations. Clin Drug Investig 2011; 31:435-8.
10. Hong Y, Rohatagi S, Habtemariam B, Walker JR, Schwartz SL, Mager DE. Population exposure-response modeling of metformin in patients with type 2 diabetes mellitus. J Clin Pharmacol 2008; 48:696-707.
11. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010; CD002967.